TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2302870
Drug: Intraperitoneal (i.p.)
Normalized name: Intraperitoneal Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal (i.p.) administration of recombinant human erythropoietin (rHuEPO) at 50 U/kg body weight
Study: 580863
Drug: guanadrel sulfate
Normalized name: guanadrel sulfate
DrugBank: Guanadrel (DB00226)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: guanadrel sulfate (5 to 20 mg orally every six hours)
Study: 21762151
Drug: 0.1%w/w o‐cymen‐5‐ol/
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1%w/w o‐cymen‐5‐ol/ 0.6%w/w zinc chloride gel to foam dentifrice
Study: 19282350
Drug: Panitumumab in
Normalized name: panitumumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panitumumab in combination with bevacizumab and chemotherapy
Study: 19282350
Drug: Bevacizumab and
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab and chemotherapy alone
Study: 9106580
Drug: Baclofen 10
Normalized name: baclofen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen 10 mg three times daily
Study: 3472436
Drug: Home blood
Normalized name: LifeSource Aneroid Home Blood Pressure Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home blood pressure (Home-BP) measured three times daily during a two week period
Study: 30393062
Drug: Antiplatelet treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet treatment (users at baseline)
Study: 30393062
Drug: Statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment (users at baseline)
Study: 10895736
Drug: Fluconazole 100
Normalized name: fluconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 100 mg tablets once per day
Study: 10895736
Drug: Clotrimazole 10
Normalized name: clotrimazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole 10 mg troches five times per day
Study: 3899840
Drug: Oral indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral indomethacin (total 200 mg) and chloroquine (total 1.5 g)
Study: 3538324
Drug: SLO4 oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLO4 oral drops
Study: 31475507
Drug: Anterior QLB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterior QLB + intravenous PCA morphine (Group B)
Study: 31475507
Drug: Intravenous PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous PCA morphine (Group C)
Study: 28426917
Drug: Internet-based cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive-behavioral therapy (iCBT) program for depression added to treatment as usual (TAU)
Study: 26021225
Drug: Protocol A
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol A (no other antibiotic administration)
Study: 26021225
Drug: Protocol B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol B (1 g of amoxicillin in the evening of the day of surgery and 1 g twice a day for 2 days after)
Study: 18803892
Drug: Intravenous 5
Normalized name: immune globulin intravenous 5% intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 5 IU oxytocin + 0.5 mg ergometrine
Study: 16580284
Drug: Oral analgesia
Normalized name: P-A-C Analgesic Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral analgesia with oxycodone‐acetaminophen
Study: 16580284
Drug: Morphine patient‐controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine patient‐controlled analgesia device
Study: 1357554
Drug: Salmeterol (42
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (42 micrograms twice daily)
Study: 1357554
Drug: Albuterol (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (180 micrograms four times daily)
Study: 3914251
Drug: Conventional steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional steroid and azathioprine therapy
Study: 25882919
Drug: Cranberry juice
Normalized name: cranberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry juice capsules (2 capsules, 2 times a day for 6 weeks)
Study: 25882919
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching placebo, 2 capsules, 2 times a day for 6 weeks)
Study: 21301848
Drug: Liposomal cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal cisplatin 200 mg/m2 combined with paclitaxel 135 mg/m2
Study: 21301848
Drug: Cisplatin 75
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 75 mg/m2 combined with paclitaxel 135 mg/m2
Study: 19625240
Drug: Alendronate therapy
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate therapy (10 mg daily)
Study: 11684630
Drug: Carvedilol (nonselective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (nonselective beta-blocker)
Study: 7814117
Drug: Minimal cavity
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal cavity preparation and composite resin only
Study: 2773832
Drug: Dietary cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary cholesterol (equal to about two egg yolks daily)
Study: 19437505
Drug: Internet‐based cognitive‐behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet‐based cognitive‐behavioral treatment with minimal contact via e‐mail
Study: 8186348
Drug: Propranolol 160
Normalized name: propranolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 160 mg long-acting (LA)
Study: 3283917
Drug: Novaluzid, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novaluzid, 10 ml four times daily
Study: 23900048
Drug: Dicholoroacetate and
Normalized name: dichloroacetate
DrugBank: Sodium dichloroacetate (DB16929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dicholoroacetate and 2 tyrosine kinase inhibitors (imatinib and sunitinib)
Study: 14737728
Drug: 0.5‐1cm deep
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5‐1cm deep marker injection
Study: 14737728
Drug: Sub‐epithelial marker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub‐epithelial marker injection
Study: 10632651
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg, Amoxycillin 1 g, and Clarithromycin 500 mg (OAC) b.d. for 1 week
Study: 10632651
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy (Bismuth subcitrate 120 mg, Tetracycline 500 mg, Metronidazole 400 mg q.d.s. plus Omeprazole 20 mg b.d.)
Study: 8959612
Drug: Focused stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focused stimulation intervention administered by parents
Study: 8959612
Drug: Delayed-treatment (control)
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-treatment (control) group
Study: 7934140
Drug: Cisplatin treatment
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin treatment in vitro
Study: 3287592
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion at a rate of 2 mU/kg/min with concomitant glucose infusion to maintain euglycaemia
Study: 3287592
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion with falling blood glucose (no glucose infusion)
Study: 12595281
Drug: Diuretic (Hypo;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic (Hypo; 100 mg/day spironolactone for 3 days)
Study: 10992369
Drug: Former PSA
Normalized name: Triple Wormer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Former PSA testing or digital rectal examination
Study: 2360466
Drug: Antiepileptic drugs
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic drugs (AEDs) as prophylactic treatment
Study: 2360466
Drug: No long-term
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No long-term AEDs treatment in patients without preoperative epilepsy
Study: 17597050
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg once daily
Study: 15114776
Drug: Postoperative intravesicular
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative intravesicular immunotherapy with ronkoleucine 1,000,000 IU
Study: 15114776
Drug: Postoperative intravesicular
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative intravesicular immunotherapy with ronkoleucine 500,000 IU
Study: 11407666
Drug: Percutaneous coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous coronary angioplasty + Helicobacter pylori eradication therapy
Study: 11407666
Drug: Percutaneous coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous coronary angioplasty + placebo treatment
Study: 12707127
Drug: IV lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV lidocaine 2 mg/kg
Study: 968923
Drug: Estrogen therapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen therapy (17‐ethinyl 1,3,5‐estratriene 3,17 diol)
Study: 968923
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (90 mg estradiol valerianate and 300 mg 17‐hydroxy‐19‐norprogesterone caproate)
Study: 21851167
Drug: Taprenepag isopropyl
Normalized name: Isopropyl Alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taprenepag isopropyl (0.005%, 0.01%, 0.015%) in unfixed combination with latanoprost 0.005%
Study: 9051282
Drug: Psychological therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological therapies for generalized anxiety disorder
Study: 29743087
Drug: α‐lipoic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: α‐lipoic acid (0.3 g/d)
Study: 29743087
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (1.3 g/d)
Study: 29743087
Drug: EPA+α‐LA (1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA+α‐LA (1.3 g/d + 0.3 g/d)
Study: 17151341
Drug: Optimized medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized medical treatment (n = 10)
Study: 11590509
Drug: HAART therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAART therapy (including indinavir or ritonavir or hard-gel saquinavir-containing regimens)
Study: 9781603
Drug: Cimetidine 800
Normalized name: cimetidine 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 800 mg twice daily by mouth
Study: 9781603
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CF at 20 mg/m2 IV push, 5-FU at 325 mg/m2 IV daily for 5 days/week, and interferon alpha-2A 5 x 10(6) units/m2 SC on days 1, 3, 5
Study: 7886777
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg aminosidine base/kg/d for 7 d
Study: 7886777
Drug: 12 mg/kg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg/kg/d for 14 d
Study: 7886777
Drug: 18 mg/kg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 mg/kg/d for 14 d
Study: 2963059
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol combined with ipratropium bromide
Study: 6344899
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol alone
Study: 6965579
Drug: Propranolol, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol, 10 mg orally every 6 hours
Study: 15379146
Drug: LAC250 (lansoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAC250 (lansoprazole 30 mg, amoxicillin 1000 mg, clarithromycin 250 mg)
Study: 15379146
Drug: LAC500 (lansoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAC500 (lansoprazole 30 mg, amoxicillin 1000 mg, clarithromycin 500 mg)
Study: 11451214
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil (2.5-80 mg)
Study: 11451214
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil (20 mg and above)
Study: 8066909
Drug: Normal dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal dose of budesonide via Nebuhaler
Study: 8066909
Drug: Half normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half normal dose of budesonide via Turbuhaler
Study: 3058131
Drug: Salbutamol dry
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol dry powder inhaled from Salbutamol cyclocaps Pharbita 0.4 mg
Study: 31048638
Drug: Combined Ahmed
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Ahmed Glaucoma Valve (AGV) implantation and trabeculectomy revision with adjunctive antimetabolite
Study: 31048638
Drug: Combined AGV
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined AGV implantation and trabeculectomy revision with adjunctive antimetabolite
Study: 27908840
Drug: Taper support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taper support intervention (psychiatric consultation, opioid dose tapering, and 18 weekly meetings with a physician assistant)
Study: 27908840
Drug: Taper support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taper support intervention
Study: 26065500
Drug: 200mg oral
Normalized name: AVANAFIL 200MG ORAL TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg oral ketoconazole twice a day plus 5% natamycin (Group B)
Study: 21377888
Drug: 0.5% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% ropivacaine (0.1 ml/kg bolus followed by 0.1 ml/kg/h continuous infusion for 48 hours)
Study: 21377888
Drug: Saline (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (0.1 ml/kg bolus followed by 0.1 ml/kg/h continuous infusion for 48 hours)
Study: 16983674
Drug: Double-pass, low-energy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-pass, low-energy treatment (8-11 J/cm²)
Study: 16983674
Drug: Single-pass, high-energy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-pass, high-energy treatment (13-14 J/cm²)
Study: 11519636
Drug: Methylphenidate (15-90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (15-90 mg)
Study: 11519636
Drug: Triazolam (0.125-0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.125-0.75 mg)
Study: 9762776
Drug: Specific IgA
Normalized name: Food specific IgA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific IgA antibodies to Dermatophagoides farinae
Study: 9762776
Drug: Specific IgA
Normalized name: Food specific IgA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific IgA antibodies to Streptococcus pneumoniae
Study: 9762776
Drug: Specific IgG
Normalized name: Mold specific IgG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific IgG antibodies to Dermatophagoides farinae
Study: 9762776
Drug: Specific IgG
Normalized name: Mold specific IgG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific IgG antibodies to Streptococcus pneumoniae
Study: 3354494
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g of fructose
Study: 3354494
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g of glucose
Study: 30056030
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg risankizumab every 4 weeks for 12 weeks (open-label intravenous therapy)
Study: 30056030
Drug: Open-label subcutaneous
Normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label subcutaneous risankizumab (180 mg) every 8 weeks for 26 weeks (maintenance phase)
Study: 30056030
Drug: Open-label intravenous
Normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label intravenous risankizumab (600 mg)
Study: 30056030
Drug: Open-label subcutaneous
Normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label subcutaneous risankizumab (180 mg)
Study: 24126646
Drug: MARS with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: MARS with conventional treatment (n = 53)
Study: 24126646
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (n = 49)
Study: 18451376
Drug: Fluoride treatment
Normalized name: 60 Second 1.23% Fluoride Treatment Dental Gel
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoride treatment (1.23 percent sodium fluoride)
Study: 17198066
Drug: 4-L polyethylene
Normalized name: polyethylene glycol 3350
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-L polyethylene glycol (PEG) solution
Study: 12975595
Drug: Quinapril (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (titrated to 40 mg/day) for 6 months
Study: 1587378
Drug: 0.625 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg/day conjugated estrogens cyclically (CE; 25 days/month)
Study: 1587378
Drug: 0.625 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg/day conjugated estrogens continuously
Study: 1587378
Drug: 50 micrograms/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 micrograms/day of transdermal 17 beta‐estradiol cyclically (24 days/month)
Study: 3983885
Drug: Nebulised salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulised salbutamol 1.25 mg
Study: 3983885
Drug: Nebulised salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulised salbutamol 2.5 mg
Study: 3983885
Drug: Nebulised salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulised salbutamol 5 mg
Study: 3983885
Drug: Control (oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (oxygen and corticosteroid treatment withheld)
Study: 16033247
Drug: 3% cork
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% cork extract gel
Study: 12445027
Drug: Co-artemether with
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Co-artemether with ketoconazole (400 mg on day 1 followed by 200 mg o.d. for 4 additional days)
Study: 1743751
Drug: Lincomycin 300
Normalized name: lincomycin 300 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lincomycin 300 mg intramuscularly daily in a single dose
Study: 6852325
Drug: Amcinonide preparations
Normalized name: Amcinonide
DrugBank: Amcinonide (DB00288)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amcinonide preparations and Betnovate cream applied once daily
Study: 6852325
Drug: Amcinonide preparations
Normalized name: Amcinonide
DrugBank: Amcinonide (DB00288)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amcinonide preparations and Betnovate cream applied twice daily
Study: 6852325
Drug: Amcinonide preparations
Normalized name: Amcinonide
DrugBank: Amcinonide (DB00288)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amcinonide preparations and Betnovate cream applied every alternate day
Study: 6852325
Drug: Amcinonide preparations
Normalized name: Amcinonide
DrugBank: Amcinonide (DB00288)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amcinonide preparations and Betnovate cream with an initial three times daily loading dose on the first day
Study: 22512509
Drug: 12 NB‐UVB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 NB‐UVB exposures over 4 weeks (mean cumulative dose 48·4 standard erythema doses)
Study: 22512509
Drug: 20 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 μg of oral cholecalciferol daily for 4 weeks
Study: 17972377
Drug: Implantable Cardioverter-Defibrillator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implantable Cardioverter-Defibrillator (ICD) therapy
Study: 17972377
Drug: ICD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD therapy for primary prevention
Study: 17972377
Drug: ICD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD therapy for secondary prevention
Study: 15814547
Drug: Tacrolimus (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus (0.2 mg/kg/day p.o.)
Study: 15814547
Drug: Cyclosporin-ME (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin-ME (7 mg/kg/day p.o.)
Study: 11823896
Drug: Chromium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chromium treatment (400 microg daily)
Study: 361057
Drug: Fenoprofen 200
Normalized name: fenoprofen 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoprofen 200 mg and Paracetamol 500 mg (combination)
Study: 361057
Drug: Fenoprofen 200
Normalized name: fenoprofen 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoprofen 200 mg (separate)
Study: 361057
Drug: Paracetamol 500
Normalized name: Paracetamol 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 500 mg (separate)
Study: 30701554
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of green cardamom for 10 weeks
Study: 25439709
Drug: Mirror therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror therapy supported by telerehabilitation
Study: 25439709
Drug: Traditional mirror
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional mirror therapy
Study: 19628486
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise intervention (30 min continuous moderate intensity cycle ergometry, twice weekly for 6 weeks)
Study: 16758177
Drug: Walking performance
Normalized name: Perform
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walking performance (measured by gait velocity and average daily strides)
Study: 9646891
Drug: Nicotine (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (administered via dermal patch)
Study: 7923540
Drug: Drug prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug prescriptions for diabetic patients